Anastrozole is a therapeutic option generally used for the endocrine management of cancer that is sensitive to hormone levels. It is commonly used for postmenopausal women who have hormone receptor-positive breast cancer.

Management of Hormone-Sensitive Cancer

The medication is commonly applied across specific conditions, including early-stage breast cancer in the adjuvant setting, locally advanced disease, and metastatic cancer. This therapeutic strategy is applied in addressing conditions marked by increased physiological stress.

It is generally used to help with reducing the likelihood of the disease recurring after initial treatments, and it is used for managing symptoms that create noticeable physiological strain in advanced disease. This provides supportive relief when symptoms interfere with routine activities and contributes to easing the overall symptom load during management phases.

---

Quick Fact: Relief for Hormone-Driven Disease Progression

Stada Anastrozole is approved for use primarily in postmenopausal women. The official regulatory labeling strictly defines several populations for whom use is prohibited or restricted.

Contraindicated Populations

Use of this medicine is contraindicated in patients who must not take it under any circumstances, including:

• Premenopausal women (those who still have menstrual cycles).
• Pregnant or breastfeeding women (Lactation).
• Patients with known hypersensitivity to anastrozole or any of the inactive ingredients.

Age and Organ-Specific Restrictions

Population Group	Regulatory Status
Pediatric Patients (Children/Adolescents)	Not recommended; safety and efficacy have not been established.
Severe Hepatic Impairment	Use requires caution; data are limited for severe impairment.
Severe Renal Impairment	Use requires caution [defined as CLCr < 30 mL/min or severe impairment].
Older Adults (Geriatric)	Approved; no dosage adjustment is typically required based on age alone.

Menopausal status must be reliably confirmed before treatment. Additionally, patients with pre-existing conditions like osteoporosis or those at risk require formal assessment of their bone mineral density before and during therapy.

Stada Anastrozole Interactions with other medicines and products

Property	Official Regulatory Information
Medicinal products with documented restrictions	Estrogen-containing therapies, Tamoxifen, Estrogen-containing herbal/dietary supplements.
Mechanistic basis of key documented interactions	Pharmacodynamic antagonism (with Estrogens); Pharmacokinetic interaction reducing drug exposure (with Tamoxifen); Metabolic neutrality (tested CYP substrates).
Population-specific interaction notes	Anastrozole exposure is officially noted to be increased in patients with moderate to severe hepatic impairment. Exposure is not altered in those with renal impairment.
Interaction-related restrictions	Contraindicated/Prohibited co-administration with Estrogen-containing therapies and Tamoxifen.

---

Official Interaction Statements

Co-administration of Estrogen-containing therapies is formally restricted because it causes pharmacodynamic antagonism, which directly counteracts the anti-estrogenic action of the medicine. The simultaneous administration of Tamoxifen is officially prohibited, as studies show it reduces Anastrozole plasma concentration by approximately 27%.

Regulatory studies establish metabolic neutrality, showing no clinically significant effect on the pharmacokinetics or metabolism of tested agents like Warfarin or Antipyrine. Taking the medicine with food is documented to decrease the rate of absorption, yet the overall extent of exposure is not affected. There are no mandatory administration separation rules listed in the regulatory documents for co-administered medicines.

The overall interaction profile is defined by prohibited combinations that either directly counteract the drug's purpose or significantly alter its systemic exposure, alongside specific notes concerning increased exposure in the presence of moderate to severe hepatic impairment.

Selective Inhibition of the Aromatase Enzyme

This mechanism focuses on the compound's core action: acting as a selective, non-steroidal inhibitor of the aromatase enzyme . By physically and reversibly binding to the enzyme's heme unit, the compound blocks the final enzymatic step in the steroidogenesis pathway responsible for converting androgens into estrogens, directly resulting in the cessation of estrogen synthesis.

Systemic Reduction in Estrogen Load

The inhibition of the aromatase enzyme, which is active in various peripheral tissues like fat and muscle, leads to a cascade effect where the overall amount of estrogen circulating in the bloodstream is significantly reduced. This results in a marked, sustained alteration in the estrogen-driven physiological state by reducing the body's total hormonal stimulus, which establishes the core physiological action of the compound.

Administration Instructions

Stada Anastrozole (generic Anastrozole) is a medicine strictly for oral use, with precise administration guidelines. The dosage and schedule are standardized for most patients, and instructions for managing missed doses are specific.

Administration Element	Guideline
Recommended Dose	One 1 milligram (mg) tablet
Route of Administration	Oral (by mouth), swallowed whole with fluids
Frequency	Once a day (daily)
Timing	Should be taken at approximately the same time each day to help maintain a consistent plasma level
Relation to Meals	May be taken with or without food
Treatment Duration	For early breast cancer, treatment is typically administered for a course of five years. For advanced disease, it is continued until the tumor progresses

Procedural Guidelines and Special Populations

Missed Dose: If a dose is forgotten, the protocol involves skipping the missed dose and taking the next dose at the usual scheduled time. Two tablets should not be taken to make up for a missed dose.

Dosage Adjustment: No change in the 1 mg dose is necessary for elderly patients or those with renal impairment. Similarly, no adjustment is generally required for patients with mild-to-moderate hepatic impairment. The medicine has not been studied in patients with severe hepatic impairment.

These administration guidelines establish the standardized, long-term protocol for the use of Anastrozole, ensuring consistent daily exposure.

Evidence for Adjuvant Treatment of Early Breast Cancer

Research for anastrozole was conducted through large-scale, randomized controlled trials (RCTs), where postmenopausal women with localized, hormone receptor-positive breast cancer were included in trials that lasted for a defined period, typically five years. The research examined outcomes related to cancer recurrence, specifically monitoring Disease-Free Survival (DFS) and the Time to Recurrence. The major trials reported measurements for Disease-Free Survival, which was a primary endpoint examined for differences among treatment arms. Overall Survival (OS) was observed in the studies, but this outcome was not the primary endpoint examined for differences between the treatment arms in the full study group. Follow-up durations were limited to approximately eight years for some key analyses, and data for certain groups remain insufficient, particularly for patients with pre-existing moderate or severe hepatic impairment.

Evidence for Treatment of Advanced Breast Cancer

The evidence was evaluated in Randomized, Multicenter Studies that examined patterns related to changes in the disease state in postmenopausal women with advanced hormone-sensitive cancer. The research examined outcomes focusing on metrics such as Objective Response Rate (ORR) and Time to Progression (TTP) in both first-line and second-line settings. The data are still emerging for use in children and adolescents, as current clinical data is not well characterized for these age groups. Limited information for long-term outcomes exists beyond the point of disease progression.

Evidence for Primary Prevention in High-Risk Women

The primary evidence was evaluated in a large, international, placebo-controlled trial focused on women at increased risk of developing the disease. The research monitored the Incidence of Breast Cancer. Long-term analysis described patterns related to cancer incidence for over ten years after randomization. Certainty remains low for the long-term effects on breast cancer mortality, as research is ongoing and the number of events has been small so far.

Long-Term Studies and Research Gaps

Long-term observation data was observed in studies for over eight years in the adjuvant setting and over ten years in the prevention setting. However, research highlights that Overall Survival was not the primary factor examined in the early breast cancer trials. Data are still emerging for specific patient subgroups, including those with certain significant non-cancer comorbidities. Research does not determine whether an individual will respond similarly to the group patterns observed.

Common questions about Stada Anastrozole (FAQ)

Q: What kind of medicine is Stada Anastrozole?

A: Stada Anastrozole is officially classified as an aromatase inhibitor. This type of medicine works by blocking an enzyme in the body called aromatase. According to regulatory documents, its main action is to reduce the amount of the hormone estrogen, which is associated with stimulating the growth of some types of breast cancer.

Q: What is the primary use of Stada Anastrozole?

A: According to the official product information, Stada Anastrozole is used to treat breast cancer in women who have reached menopause. It is specifically indicated for hormone receptor-positive early breast cancer and for advanced breast cancer.

Q: Does Stada Anastrozole cure cancer?

A: The official product information does not state that Stada Anastrozole is a cure for cancer. Instead, it is used as a treatment to help manage and control the disease. Official product information suggests it is used to help manage the disease by slowing the growth of tumors that rely on estrogen.

Q: Can I take Stada Anastrozole if I have not gone through menopause yet?

A: Regulatory documents state that Stada Anastrozole is primarily indicated for use in postmenopausal women. The official information specifies that this medicine is not intended for premenopausal women, even for hormone receptor-positive early breast cancer. Eligibility for treatment is a medical decision based on your menopausal status, as indicated in the product information.

Q: Is it safe to take Stada Anastrozole with an estrogen-containing medicine?

A: Official information indicates that Stada Anastrozole should not be taken at the same time as medicines that contain estrogen. These include estrogen replacement therapies or oral contraceptives. Regulatory documents caution against this combination because estrogen-containing medicines may potentially interfere with the effectiveness of anastrozole.

Q: Can men take Stada Anastrozole for breast cancer?

A: The official product information and available studies focus on the use of Stada Anastrozole to treat postmenopausal women with breast cancer. There is no standard regulatory information available for its use in men for the same purpose.

Q: What should I do if I miss a dose of Stada Anastrozole?

A: Official product instructions provide guidance on missed doses, which typically involves taking the dose when remembered unless it's nearly time for the next dose. You should never take a double dose to compensate for a missed one. The specific instructions for managing a missed dose are detailed in the patient leaflet accompanying the medicine.

Q: Can Stada Anastrozole affect my bones?

A: Official information and clinical studies indicate that Stada Anastrozole can sometimes be associated with a reduction in bone mineral density. This potential effect may increase the risk of fractures. Your overall care plan may include monitoring and management strategies to address bone health.

Q: How long do I usually need to take Stada Anastrozole?

A: According to regulatory sources, the duration of treatment with Stada Anastrozole can vary based on the patient’s specific condition and the overall treatment plan. For early breast cancer, treatment is often recommended for a specific time period, such as five years. The final duration of treatment is determined by the prescribing healthcare professional.

How to Store and Dispose of Stada Anastrozole?

The official labeled instructions define strict conditions for storing and disposing of Stada Anastrozole to maintain drug stability and environmental safety.

Storage Requirements

The tablets must be stored at Controlled Room Temperature, which is between 20^circ to 25 C (68^circ to 77 F), with temporary excursions permitted up to 30 C. It is mandatory to keep the medicine in its original, tightly closed container, protected from both moisture and light. The tablets must be kept out of the sight and reach of children to prevent accidental harm.

Disposal Instructions

Official regulatory guidelines explicitly state that this medication must not be thrown away with household waste or flushed down the toilet (via wastewater). Unused, expired, or unwanted tablets should be returned to a pharmacy or local authorized collection point for proper pharmaceutical waste disposal, according to regional environmental regulations.